Q1 FY27 results: Revenue up 86% YoY to Rs 375 cr, PAT up 27%

Revenue Growth 20pctPat Growth 25pctRelated Party TransactionsResults View source PDF Explain this filing

VOEPL · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-3.6%Reaction day

₹521.95

prior close

₹547.00

announcement price

After-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used+0.2%-3.7% vs market

Consumer Durables peers, median of 194sector · industry level-0.1%-3.5% vs sector

On the reaction day the stock moved 3.7 pts less than Nifty Microcap 250 and 3.5 pts less than its Consumer Durables peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-4.8

10m

-5.0

15m

-6.0

30m

-5.6

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-3.6+0.2-3.7-0.1-3.5

Next day

-2.3+0.2-2.6-0.6-1.8

-6.2+0.4-6.6-1.0-5.2

-9.0+0.7-9.7-1.3-7.8

-5.0+0.1-5.1-0.8-4.1

-7.1+0.7-7.7-0.9-6.2

-6.1+1.2-7.3-0.6-5.5

15d

+5.4+0.7+4.6-2.3+7.7

-6.3-1.2-5.1-3.7-2.6

-3.1-1.1-1.9-7.0+3.9

—————

UpDownMarket · Nifty Microcap 250Sector · Consumer Durables peers, median of 194Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Virtuoso Optoelectronics reported Q1 FY27 results. Standalone revenue grew 86% YoY to Rs 375.47 crores from Rs 201.89 crores. Standalone PAT rose 27% YoY to Rs 8.39 crores. Consolidated revenue was Rs 375.88 crores, PAT was Rs 9.05 crores. Board approved conversion of Rs 9.99 crores inter-corporate deposit to subsidiary VPPL into equity. Internal auditor resigned citing professional commitments, replaced by new firm.

Likely market impact

Strong Q1 growth in revenue and profit is positive. Internal auditor change and subsidiary ICD conversion are largely neutral for shareholders.